2026 ASCO Breast Cancer Highlights: Triple Negative Breast Cancer

Harold Burstein, MD, PhD, and Ana C. Garrido-Castro, MD discuss new antibody drug conjugate treatment options in first line triple negative breast cancer.

October 15, 2026

Dana-Farber

Original Source(s)

Dana-Farber

2026 ASCO Breast Cancer Highlights: Triple Negative Breast Cancer

October 15, 2026

Related Content

The Medicine Maker

Building a Pre-Disease Data Map

Mayo Clinic and Thermo Fisher launch a large-scale multi-omics resource designed to reveal disease before symptoms appear

October 7, 2026
2 min

Blood Cancer Journal

Overall survival of Black patients with newly diagnosed multiple myeloma in the era of triplet and quadruplet therapies

by Hamlet Gasoyan, Shahzad Raza, Michael B. Rothberg, Jeffrey D. Kovach, Nicholas J. Casacchia, Jason Valent, Faiz Anwer
October 7, 2026

Surgical Endoscopy

Learning curve of robotic pancreaticoduodenectomy: a CUSUM and risk-adjusted CUSUM analysis of 120 consecutive cases

by Giuseppe Quero, Matteo Aulicino, Lodovica Langellotti, Gloria Santoro, Giuseppe Massimiani, Flavia Taglioni, Giuseppe Daloiso, Roberta Menghi, Federica Marzi, Antonio Pio Tortorelli, Claudio Fiorillo, Claudia Ferrantone, Davide De Sio, Mario Lettieri, Rossella Sepe, Vincenzo Tondolo, Sergio Alfieri
October 7, 2026